重组人粒细胞集落刺激因子在乳腺癌化疗中的疗效观察

Curative Effect Observation of Recombinant Human Granulocyte Colony Stimulating Factor in Breast Cancer Chemotherapy

目的 观察重组人粒细胞集落刺激因子（ rhG-CSF）对乳腺癌术后化疗骨髓抑制的临床疗效. 方法 将乳腺癌术后行TE/TEC方案化疗的患者,随机分为2组,2组患者行化疗前均给予“地塞米松片”、“帕洛诺司琼注射液”,在此基础上,治疗组化疗结束24~48h后给予“重组人粒细胞集落刺激因子”治疗. 观测2组患者血常规及发热性中性粒细胞减少症（ febrile neutropenia ,FN）的发生率,并对指标进行统计学分析. 结果 化疗后治疗组患者白细胞总数与中性粒细胞数均高于对照组,FN发生率低于对照组,差异均有统计学意义（ P〈0.05）.治疗组血小板减少、血红蛋白减少发生率与对照组比较差异无统计学意义（P〉0.05）. 结论 重组人粒细胞集落刺激因子治疗乳腺癌术后行紫杉类和蒽环类药物联合化疗所致的骨髓抑制具有较好疗效,安全性高.

Objective To observe the clinical efficacy of Recombinant Human Granulocyte Colony Stimula-ting Factor （ rhG-CSF ） in myelosuppression after postoperative chemotherapy for breast cancer .Methods The breast cancer patientswere randomly divided into 2 groups, received the postoperative TE/TEC scheme chemotherapy .Two groups of patients before chemotherapy were given antiemetic therapy , including Dexamethasoneand Palonosetron injec-tion.Then,treatment group was given ＂recombinant human granulocyte colony stimulating factor＂,after the Chemothera-py over 24~48h observed 2 groups of patients with blood routine and febrile neutropenia （febrile neutropenia,FN） inci-dence ,and analysed the statistical indicators .Results Total number of white blood cells and neutrophils in chemothera-py treatment group patients were higher than the control group ,FN rate lower than the control group ,the difference was statistically significant（P〈0.05）.Compared with controls,the incidence of thrombocytopenia and hemoglobin decrease in the treatment group had no statistical significance （ P〉0 .05 ） .Conclusion RhG-CSF preventive treatment for breast cancer postoperative yew class and anthracycline-based drugs in combination with bone marrow suppression caused by chemotherapy has a good curative effect ,which is safe .